Reviewing Drug Safety Risk Management Based on Drug Withdrawl Experiences in USA.

Abstract

Abstract: Objective To analyze causes of drug withdrawls in USA and to emphasize that risk management of post-marketing drugs is very important to the public health. Methodse Medical literatures and US FDA website were searched and analyzed regarding information on drugs that have been withdrawn or removed from the market in USA. Results A total of 72 products were withdrawn or removed from USA during 1964 and 2009. The common safety causes of withdrawal include cardiovascular events, carcinogenic risk, liver toxicity, blood disorders, skin disorders, neurologic/mental disorders, renal toxicity, and so on. Conclusion Risk management should be considered throughout a drug’s lifecycle from development to post-market usage. Risk management of post-marketing drugs is particularly important. Drug withdrawal is the last approach for post-marketing safety risk management.

Key words: post-marketing drug, drug safety, risk management, withdrawal, FDA

CLC Number:

R954

GUO Xiao-xin, DU Xiao-xi, XUE Song-lin. Reviewing Drug Safety Risk Management Based on Drug Withdrawl Experiences in USA.[J]. Chinese Journal of Pharmacovigilance, 2011, 8(4): 212-215.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2011/V8/I4/212

References

[1] Janice K.bush, Wanju S.Dai, Gretchen S. Dieck, et al. The Art and Science of Risk Management[J]. Drug Safety,2006, 28 (1):1-18.
[2] ICH Guideline for industry: E1A. The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions[EB/OL]. [2006-11-23].http://www.fda.gov/cdr/guidance/ichela.pdf.
[3] FDA List of Drug Products that Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness[EB/OL].[ 2010-12-09].http://www.fda.gov/ohrms/dockets/98fr100898b.txt.
[4] FDA Drugs for Human Use Containing Bithionol[EB/OL].[2010-12-08].http://www.fda.gov/ohrmsdockets/ac/98/briefingbook/1998-3454B1_03_WL05.pdf.
[5] FDA Drug Products Containing Adrenal Cortex Extract or Adrenal Cortex Injection l[EB/OL].[2010-12-08].http://www.fda.gov/ohrms/dockets/ac/98/briefingbook/1998-3454B1_03_WL02.pdf.
[6] FDA Phenformin Hydrochloride; Withdrawal of Approval of New Drug Application; Final Decision[EB/OL].[2010-10-29].http://www.fda.gov/ohrms/dockets/ac/98/briefingbook/1998-3454B1_03_WL38.pdf.
[7] FDA HSS News[EB/OL].[2010-12-08].http://www.fda.gov/ohrms/dockets/ac/98/briefingbook/1998-3454B1_03_WL04.pdf.]
[8] FDA FDA Announces. Withdrawal of Fenfluramaine and Dexfenfluramine[EB/OL]. [2010-12-03].http://www.fda.gov/ohrms/dockets/ac/98/briefingbook/1998-3454B1_03_WL22.pdf.
[9] FDA Azaribine Tablets Withdrawal of Approval of New Drug Application[EB/OL].[2010-12-08].http://www.fda.gov/ohrms/dockets/ac/98/briefingbook/1998-3454B1_03_WL03.pdf.
[10] FDA Wyeth-Ayerst Laboratories Announces the Withdrawal of Druact from the market[EB/OL].[2010-12-09].http://www.fda.gov/ohrms/dockets/ac/98/briefingbook/1998-3454B1_03_WL06.pdf.
（因版面有限,部分参考文献省略,如有需要,请联系编辑部）

[1]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.
[2]	CAO Kai, QIAN Peipei, GAO Xin, YANG Futian, ZHAO Liang, XU Bingxin, ZHANG Xianjun. Mining of Risk Signals Adverse Events Related to Drug-Induced Salivary Gland Calculus Based on FAERS Database [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 799-804.
[3]	CHEN Lingbin, HUANG Zhixiong, ZHENG Cailin, WU Jinneng, CHEN Zhou. Adverse Event Signals for Osimertinib-Induced Muscle Toxicity Based on FAERS Database [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 447-451.
[4]	YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
[5]	ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024.
[6]	LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming. Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
[7]	LU De, XU Wenyan, LIU Jinxin, PEI Yusheng. Discussion and analysis of bacterial endotoxin problems in FDA warning letters [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 857-862.
[8]	ZHONG Hong, CHEN Hong, ZHANG Xuanyi, DENG Huiyuan, LUO Xianglin, WAN Jie, KONG Wenqiang. Detection and analysis of signals of adverse events induced by deferasirox based on FAERS [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 931-935.
[9]	SHI Guanhong, WANG Qi, SUN Hao, CHEN Yanjie, CHU Ziyan, JIANG Ao, TANG Zaixiang, LIU Jingfang. Safety signal analysis of antidepressants use in fetus and neonate based on US FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 687-692.
[10]	WANG Chunnan, QIN Shiru, ZHANG Meng, SONG Haibo, LIU Junchang, LI Ge, SUN Feng. Evaluation of drug safety with multicenter real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 703-708.
[11]	CAO Ying, ZHOU Huziwei, ZHU Lan, WANG Shengfeng. Management of compound glycyrrhiza oral solution and recommendations [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 529-534.
[12]	SU Xiaohan, ZENG Jiao, LI Xue, LIU Lixin, HOU Lingmi, LI Jinsui. Adverse events of abemaciclib in breast cancer patients based on US FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 580-586.
[13]	LIU Jie, ZHANG Jianmin, ZHANG Xiaomeng, LIU Fang, SONG Yuan, ZHONG Xuli. Management of risks to pediatric medications based on drug instructions of Chinese patent medicines in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 422-427.
[14]	YOU Xiaoyan, ZHENG Yingying, WANG Xianying. Data-mining and analysis of adverse events signals for infliximab based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 335-340.
[15]	WU Tingxi, ZHAO Zhigang, SHI Yanfeng, ZHANG Yang, ZHANG Yinan, ZHU Bin. Risk assessment of colchicine-associated neurological adverse events based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 341-345.